Is Kura Oncology, Inc. (KURA) a Buy, Sell, or Hold?
Kura Oncology, Inc.
NASDAQ:KURA
$11.27 USD
$0.03 (0.27%)
- Volume
- 421.19K
- Average Volume
- 1.8M
- Market Capitalization
- $1B
- P/E Ratio
- -3.36
- Dividend Yield
- 0.00%
- Price Target
- $24.00
- Year High
- $12.49
- Year Low
- $5.45
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.15
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Troy Wilson |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | KURA |
| CUSIP | 50127T109 |
| CIK | 0001422143 |
| Web | https://kuraoncology.com |
| Phone | 858 500 8800 |
| Currency | USD |
| Employees | 260 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.22 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.15 |
| Quick Ratio | 6.14 |
| Cash Ratio | 0.39 |
Sales & Book Value
| Annual Sales | $67.48M |
| Price / Sales | 13.97 |
| Cash Flow | -0.95 |
| Price / Cash Flow | -11.85 |
| Price / Book | 9.26 |
Price Target and Rating
| Average Stock Price Forecast | $24.00 |
| High Stock Price Forecast | $24.00 |
| Low Stock Price Forecast | $15.00 |
| Forecast Upside/Downside | -53.04% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 17 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.18 |
| Trailing P/E Ratio | -3.36 |
| PEG Ratio | 0.08 |
| P/E Growth | 0.08 |
| Net Income | $-278.67M |
| Net Margin | -411.19% |
| Pretax Margin | -411.08% |
| Return on Equity | -141.95% |
| Return on Assets | -45.14% |
Financials Score
| AltmanZ Score | -2.02 |
| Piotroski Score | 2.00 |
| Working Capital | 522.29M |
| Total Assets | 652.55M |
| Ebit | -293.42M |
| Market Cap | 968.53M |
| Total Liabilities | 544.67M |
Poll Results
About Kura Oncology, Inc. (NASDAQ:KURA) Stock
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California. ...
2026-07-14 07:02:00
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –
Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win
2026-07-08 07:23:47
Kura Oncology is positioning ziftomenib (KOMZIFTI) as a combination backbone in AML, not just a relapsed/refractory monotherapy. KURA's robust cash position, bolstered by Kyowa Kirin payments, is expected to fund the pivotal KOMET-017 trial through the topline readout in 2028. Recent combination data show high remission rates and tolerability, supporting the platform thesis and expanding addressable AML market potential.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-03 07:30:00
SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 68,750 shares of common stock to five (5) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
2026-06-12 19:02:09
Kura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML Transcript
2026-06-11 08:02:00
– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-05 07:30:00
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 53,000 shares of common stock to four (4) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
2026-06-04 02:52:12
Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib Transcript
2026-06-03 06:53:00
– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients –
Frequently Asked Questions
-
What is the current Kura Oncology, Inc. (KURA) stock price?
-
Kura Oncology, Inc.(NASDAQ:KURA) stock price is $11.27 in the last trading session. During the trading session, KURA stock reached the peak price of $12.49 while $5.45 was the lowest point it dropped to. The percentage change in KURA stock occurred in the recent session was 0.27% while the dollar amount for the price change in KURA stock was $0.03.
-
KURA's industry and sector of operation?
-
The NASDAQ listed KURA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of KURA?
-
Roger Bakale | Senior Vice President of Manufacturing & Supply Chain
Troy Edward Wilson | Chairman, Chief Executive Officer & President
Kathleen Ford | Chief Operating Officer
Francis J. Burrows | Chief Scientific Officer
Mollie Leoni | Chief Medical Officer -
How many employees does KURA have?
-
Number of KURA employees currently stands at 260. KURA operates from 4930 Directors Place, San Diego, CA 92121, US.
-
Link for KURA official website?
-
Official Website of KURA is: https://kuraoncology.com
-
How do I contact KURA?
-
KURA could be contacted at phone #858 500 8800 and can also be accessed through its website. KURA operates from 4930 Directors Place, San Diego, CA 92121, US.
-
How many shares of KURA are traded daily?
-
The average number of KURA shares traded daily for last 3 months was 1.8M.
-
What is the market cap of KURA currently?
-
The market value of KURA currently stands at $1B with its latest stock price at $11.27